浙江华海药业股份有限公司初创于1989年,其前身为临海市汛桥合成化工厂,2001年1月整体变更设立为浙江华海药业股份有限公司。2003年3月,公司股票在上海证券交易所成功上市。股票简称:华海药业,股票代码:600521
今年4月份,FDA派出两名官员检查了华海药业的成品药工厂。
In April, the FDA sent two officials to inspect Huahai's finished-dosage factory.
华海药业过去的业务重点是高血压药物,但现在已开始生产多种仿制药。
Huahai used to focus on hypertension drugs but now makes a stable of generic medicines.
华海药业有90%的收入来自于原料药,其产品出口到了30多个国家。
Huahai currently gets 90% of its revenue from APIs, most of which are exported to drug companies in more than 30 countries.
应用推荐